Fortis Healthcare Ltd.
Pharma · NSE
52-week range
₹646 – ₹1,104
From 52w high
-13.8%
RSI (14)
64.8
vs SMA 50 / 200
↑ 50 · ↑ 200
Fortis Healthcare trades at ₹952.35, up 38.82% over 12 months and above both its 50-DMA (₹882.66) and 200-DMA (₹917.44), with an RSI of 64.84. The trailing PE of 74.55 (forward PE 50.10) is the highest among 6 sector peers, while a 5-year earnings CAGR of -21.6% contrasts with 5-year revenue growth of 17.5%. Debt-to-equity stands at 32.96 with a rising debt trend, and the quality score of 32/100 ranks 4th of 6 in its peer group.
- ✓Revenue has grown at a 17.5% CAGR over 5 years, reflecting sustained top-line expansion in a sector with structurally growing healthcare demand.
- ✓Free cash flow has been positive in 4 of the last 5 years, indicating the core hospital operations generate cash despite elevated debt levels.
- ✓Price is trading above both the 50-DMA (₹882.66) and 200-DMA (₹917.44), with a 1-year gain of 38.82% and a 3-month gain of 10.76%.
- ✓Mean analyst rating of 1.44 across 18 analysts (1–5 scale, lower = more constructive), indicating a skew toward the constructive end of the scale among covering analysts.
- ✗5-year earnings CAGR of -21.6% indicates that sustained revenue growth has not translated to profit growth; profit margin stands at 10.94% with a consistency score of 37/100.
- ✗Debt-to-equity of 32.96 with a rising debt trend is materially elevated relative to the non-bank healthcare sector context; ROE data is unavailable, making return-on-capital assessment incomplete.
- ✗Trailing PE of 74.55 is the highest in the 6-stock peer group; quality score of 32/100 ranks 4th, while Max Healthcare and Sun Pharma score 54 and 50 respectively.
- ✗ROE has not exceeded 15% in any of the past 5 measurable years (0 of 5), and the persistency score of 37/100 reflects weak consistency of returns across the measured period.
- ·ICICI Securities estimated Q4 PAT at ₹243.3 crore, up approximately 7.4% year-on-year, suggesting near-term earnings may show improvement even as the 5-year trend remains negative.
- ·Fortis granted 1.32 crore employee stock options under its ESOP 2026 scheme in late April 2026, a non-cash compensation event that will dilute equity and affect per-share metrics going forward.
- ·The stock appeared in a list of 14 names crossing above their 200-DMA in late April 2026, coinciding with the price reclaiming ₹917 and sustaining the move through early May 2026.
- ?If revenue has compounded at 17.5% annually while earnings have declined at 21.6% annually over 5 years, what specific cost lines or non-operating charges explain the divergence, and have those factors structurally changed?
- ?With a debt-to-equity of 32.96 and a rising debt trend, what is the interest coverage ratio and how does debt maturity profile compare to the hospital expansion capex pipeline?
- ?Does the trailing PE of 74.55 — the highest among peers — reflect a premium for capacity expansion optionality, or does it assume an earnings recovery that the 5-year trajectory has not yet delivered?
- ?How does the ESOP 2026 grant of 1.32 crore options affect fully-diluted EPS projections, and what vesting timeline and exercise price were disclosed alongside the grant?
PE
74.6
Forward PE
50.1
ROE
—
Profit margin
+10.9%
D/E
32.96
Dividend yield
+0.1%
Quality score
32/100
ROE 5y above 15%
0/5 yrs
FCF 5y positive
4/5 yrs
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.Analysis generated 11 May 2026.